ZYTIGA: payments to doctors
Payments that named ZYTIGA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $814K
- Providers
- 899
- Transactions
- 1,878
- Average per transaction
- $433
The per-transaction average — $433 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 899 providers the average total is $905, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $782,883 | 96.2% |
| Janssen Global Services, LLC | $21,891 | 2.7% |
| Janssen Scientific Affairs, LLC | $7,974 | 1.0% |
| Janssen Products, LP | $875 | 0.1% |
| Janssen Research & Development, LLC | $101 | 0.0% |